Nucleotide Delivery from cycloSaligenyl-3′-azido-3′-deoxythymidine Monophosphates (cycloSal-AZTMP)

European Journal of Organic Chemistry

Volumn , Issue 5, 1998, Pages 837-846

  Meier, Chris ^a   De Clercq, Eric ^b   Balzarini, Jan ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

AZT; cyclosal pro nucleotide; HIV chemotherapy; Nucleotide delivery; Prodrugs

Indexed keywords

EID: 0003188936     PISSN: 1434193X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0690(199805)1998:5<837::AID-EJOC837>3.0.CO;2-7     Document Type: Article

References (66)

1. A preliminary account of this work was presented at the 9th International Conference on Antiviral Research, Fukushima, Japan, May 19-24, 1996; Congress abstract: C. Meier, M. Lorey, E. De Clercq, J. Balzarini, Antiviral Res. 1996, 28, A29, and at the 4th Swedish-German Symposium, Reisensburg, Germany, November 23-26, 1996; Congress abstract: C. Meier, E. De Clercq, J. Balzarini, Nucleosides & Nucleotides 1997, 16, 793-796.
2. A preliminary account of this work was presented at the 9th International Conference on Antiviral Research, Fukushima, Japan, May 19-24, 1996; Congress abstract: C. Meier, M. Lorey, E. De Clercq, J. Balzarini, Antiviral Res. 1996, 28, A29, and at the 4th Swedish-German Symposium, Reisensburg, Germany, November 23-26, 1996; Congress abstract: C. Meier, E. De Clercq, J. Balzarini, Nucleosides & Nucleotides 1997, 16, 793-796.
3. E. De Clercq, J. Med. Chem. 1995, 38, 2491-2517.
4. E. De Clercq, AIDS Res. Human Retroviruses 1992, 8, 119-134.
5. J. Balzarini, Pharm. World Sci. 1994, 16, 113-126.
6. P. Herdewijn, J. Balzarini, E. De Clercq, R. Pauwels, M. Baba, S. Broder, H. Vanderhaeghe, J Med. Chem. 1987, 30, 1270-1278.
7. P. A. Furman, J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehrmann, D. P. Bolognesi, S. Broder, Proc. Natl. Acad. Sci., USA 1986, 83, 8333-8337.
8. O. Heidenreich, F. Eckstein, Nucleosides & Nucleotides 1991, 10, 535-536.
9. Z. Hao, D. A. Cooney, N. R. Hartman, C.-F. Perno, A. Fridland, A. L. DeVico, M. G. Sarngadharan, S. Broder, D. G. Johns, Mol. Pharmacol. 1988, 34, 431-435.
10. Z. Hao, D. A. Cooney, D. Farquhar, C. F. Perno, K. Zhang, R. Masood, Y. Wilson, N. R. Hartman, J. Balzarini, D. G. Johns, Mol. Pharmacol. 1990, 37, 157-163.
11. P. Herdewijn, J. Balzarini, E. De Clercq, in: Advances in Antiviral Drug Design (Ed. E. De Clercq), 1993, Vol. 1, 233-318.
12. J. Balzarini, P. Herdewijn, E. De Clercq, J. Biol. Chem. 1989, 264, 6127-6133.
13. J. Cinatl Jr, B. Gröschel, R. Zehner, J. Cinatl, C. Périgaud, G. Gosselin, J.-L. Imbach, H. W. Doerr, Antiviral Chem. & Chemother. 1997, 8, 343-352.
14. F. Dianzani, G. Antonelli, O. Turriziani, E. Riva, E. Swimeoni, C. Signoretti, S. Strosselli, M. Cianfriglia, AIDS Res. Human Retroviruses 1994, 10, 1471-1478.
15. V. J. Stella, J. Med. Chem. 1980, 23, 1275-1285.
16. A. A. Sinkula, S. H. Yalkowsky, J. Pharm. Sci. 1980, 64, 181-210.
17. C. Périgaud, J.-L. Giradet, G. Gosselin, J.-L. Imbach, in: Advances in Antiviral Drug Design. (Ed. E. De Clercq), 1996, Vol. 2, 147-172.
18. R. J. Jones, N. Bischofberger, Antiviral Res. 1995, 27, 1-17 and cited literature.
19. Y. Henin, C. Gouyette, O. Schwartz, J.-C. Debouzy, J.-M. Neumann, T. Huynh-Dinh, J. Med. Chem. 1991, 34, 1830-1837.
20. C. Meier, J.-M Neuman, F. André, Y. Henin, T. Huynh-Dinh, J. Org. Chem. 1992, 57, 7300-7308.
21. C. McGuigan, C. Nickson, J. Petrick, A. Karpas, FEBS Lett. 1992, 310, 171-174.
22. C. McGuigan, C. Nickson, T. J. O'Connor, D. Kinchington, Antiviral Res. 1992, 17, 197-212.
23. W. Thomson, D. Nicholls, W. J. Irwin, J. S. Al-Mushadani, S. Freeman, A. Karpas, J. Petrik, N. Mahmood, A. J. Hay, J. Chem. Soc., Perkin Trans, 1 1993, 1239-1245.
24. A. D. Briggs, M. Camplo, S. Freeman, J. Lundström, B. G. Pring, Tetrahedron, 1996, 47, 14937-14950.
25. D. Farquhar, S. Khan, D. N. Srivastva, P. P. Saunders, J. Med. Chem. 1994, 37, 3902- 3909.
26. D. Farquhar, S. Khan, M. C. Wilkerson, B. S. Anderson, Tetrahedron Lett. 1995, 36, 655-658.
27. J. K Sastry, P. N. Nehete, S. Khan, B. J. Nowak, W. Plunkett, R. B. Arlinghaus, D. Farquhar, Mol. Pharmacol 1992, 41, 441-445.
28. I. Lefebvre, C. Périgaud, A. Pompon, A.-M. Aubertin, J.-L. Girardet, A. Kirn, G. Gosselin, J.-L. Imbach, J. Med. Chem. 1995, 38, 3941-3950.
29. J.-L. Girardet, C. Périgaud, A.-M. Aubertin, G. Gosselin, A. Kirn, J.-L. Imbach, Bioorg. Med. Chem. Lett. 1995, 5, 2981-2984.
30. C. Périgaud, A.-M. Aubertin, S. Benzaria, H. Pelicano, J.-L. Girardet, G. Maury, G. Gosselin, A. Kirn, J.-L. Imbach, Biochem Pharmacol. 1994, 48, 11-14.
31. F. Puech, A. Pompon, I. Lefebvre, G. Gosselin, J.-L. Imbach, Bioorg. Med Chem. Lett. 1992, 2, 603-606.
32. F. Puech, G. Gosselin, I. Lefebvre, A. Pompon, A.-M. Aubertin, A. Kirn, J.-L. Imbach, Antiviral Res. 1993, 22, 155-174.
33. C. McGuigan, R. N. Pathirana, J. Balzarini, E. De Clercq, J. Med. Chem. 1993, 36, 1048-1052.
34. C. McGuigan, D. Cahard, H. M. Sheeka, E. De Clercq, J. Balzarini, J. Med. Chem. 1996, 39, 1748-1753.
35. J. Balzarim, A. Karlsson, S. Aquaro, C.-F. Perno, D. Cahard, L. Naesens, E. De Clercq, C. McGuigan, Proc. Natl. Acad. Sci. USA 1996, 93, 7295-7299.
36. J. Balzarini, H. Egberink, K. Hartmann, D. Cahard, T. Vahlenkamp, E. Thormar, E. De Clercq, C. McGuigan, Mol. Pharmacol. 1996, 50, 1207-1213.
37. J. Baizarini, J. Kruining, O. Wedgwood, C. Pannecouque, S. Aquaro, C. F. Perno, L. Naesens, M. Witvrouw, R. Heijtink, E. De Clercq, C. McGuigan, FEBS Lett. 1997, 410, 324-328.
38. C. Meier, L. w. Habel, J. Balzarini, E. De Clercq, Liebigs Ann. 1995, 2203-2208.
39. C. Meier, Angew. Chem 1993, 105, 1854-1856; Angew. Chem., Int. Ed. Engl. 1993, 32, 1704-1706.
40. C. Meier, Angew. Chem 1993, 105, 1854-1856; Angew. Chem., Int. Ed. Engl. 1993, 32, 1704-1706.
41. C. Meier, L. W. Habel, J. Balzarini, E. De Clercq, Liebigs Ann. 1995, 2195-2202.
42. C. Meier, L. W. Habel, W. Laux, J. Balzarini, E. De Clercq, Nucleosides & Nucleotides 1995, 14, 759-762.
43. L. W. Habel, C. Meier, Nucleosides & Nucleotides 1997, 16, 1311-1314.
44. C. Meier, Angew. Chem. 1996, 108, 77-79; Angew. Chem., Int. Ed. Engl. 1996, 35, 70-72.
45. C. Meier, Angew. Chem. 1996, 108, 77-79; Angew. Chem., Int. Ed. Engl. 1996, 35, 70-72.
46. C. Meier, T. Knispel, M. Lorey, J. Balzarini, Int. Antiviral News 1997, 5, 183-185.
47. C. Meier, T. Knispel, M. Lorey, J. Balzarini, GIT Laborfachzeitschrift, 1997, 41, 965-967.
48. C. Meier, University of Würzburg, 1997, unpublished results.
49. C. Meier, M. Lorey, E. De Clercq, J. Balzarini, Bioorg. Med. Chem. Lett. 1997, 7, 99-104.
50. C. Meier, T. Knispel, E. De Clercq, J. Balzarini, Bioorg. Med. Chem. Lett 1997, 7, 1577-1582.
51. Beside the anti-HIV active dideoxynucleosides mentioned here, the cycloSal-concept has also been applied to the anti-tumor agent 5-fluoro-2′-deoxyuridine:
52. C. Meier, M. Lorey, E. De Clercq, J. Balzarini, Nucleosides & Nucleotides 1997, 16, 1303-1306.
53. M. Lorey, C. Meier, E. De Clercq, J. Balzarini, Nucleosides & Nucleotides 1997, 16, 789-792.
54. S. Rim, K. L. Audus, R. T. Borchardt, Int. J. Pharm. 1986, 32, 79-85.
55. T p Zimmermann, W. B. Mahony, K. L. Prus, J. Biol. Chem. 1987, 262, 5748-5754.
56. Using a somewhat different methodology, a Pa value of 0.96 was determined for AZT (1): J. Balzarini, J. M. Cools, E. De Clercq, Biochem. Biophys. Res. Commun. 1989, 158, 413-422.
57. It is well known in the literature that phosphodiesters are extremely stable towards chemical hydrolysis at physiological pH values: C. A. Bunton, M. M. Mhala, K. G. Oldham, C. A. Vernon, J. Chem Soc. 1960, 3293-3301. Even the "reactive" diphenylphosphate showed a half-life of 180 years(!) at pH 7.0 and 100°C: A. J. Kirby, M. Younas, J. Chem. Soc. (B) 1970, 510-513.
58. It is well known in the literature that phosphodiesters are extremely stable towards chemical hydrolysis at physiological pH values: C. A. Bunton, M. M. Mhala, K. G. Oldham, C. A. Vernon, J. Chem Soc. 1960, 3293-3301. Even the "reactive" diphenylphosphate showed a half-life of 180 years(!) at pH 7.0 and 100°C: A. J. Kirby, M. Younas, J. Chem. Soc. (B) 1970, 510-513.
59. Enzymatically catalyzed approaches have also shown some limitations in the hydrolyses of non-natural products: G. Valette, A. Pompon, J.-L. Girardet, L. Cappellacci, P. Franchetti, M. Grifantini, P. La Colla, A. G. Loi, C. Périgaud, G. Gosselin, J.-L. Imbach, J. Med. Chem. 1996, 39, 1981-1990.
60. W. Thomson, D. Nicholls, A. G. Mitchell, J. A. Corner, W. J. Irwin, S. Freeman, J. Chem. Soc., Perkin Trans. 1 1993, 2303-2308.
61. A. G. Mitchell, D. Nicholls, W. J. Irwin, S. Freeman, J. Chem. Soc., Perkin Trans. 2 1992, 1145-1150.
62. C.-F. perno, R Yarchoan, J. Balzarini, A. Bergamini, G. Milanese, R. Pauwels, E. De Clercq, G. Rocci, R. Calio, Antiviral Res. 1992, 17, 289-304.
63. A. Fridland, M.C. Connelly, R. Ashmun, Mol. Pharmcol. 1995, 49, 829-837.
64. A. Wissner, M. L. Carroll, J. Med. Chem. 1992, 35, 1650-166.
65. M. Popovic, M. G. Sarngadharan, E. Read, R. C. Gallo, Science 1984, 224, 497-500.
66. J. Balzarini, L. Naesens, J. Slachmuylders, H. Niphuis, I. Rosenberg, A. Holy, H. Schellekens, E. De Clercq, AIDS 1991, 5, 21-28.